Cosentyx (secukinumab) prefilled syringe — United Healthcare

Initial criteria

• Diagnosis of active non-radiographic axial spondyloarthritis
• One of the following: (a) History of failure to two NSAIDs at maximally indicated doses, each ≥4 weeks, unless contraindicated or adverse effects OR (b) Previously treated with a targeted immunomodulator FDA-approved for non-radiographic axial spondyloarthritis (e.g., Cimzia, Rinvoq) OR (c) Currently on Cosentyx therapy with documentation and has not received manufacturer supplied sample or assistance
• Not receiving Cosentyx in combination with another targeted immunomodulator [Enbrel, Cimzia, Simponi, Orencia, adalimumab, Xeljanz, Olumiant, Rinvoq]
• Prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• Documentation of positive clinical response to Cosentyx therapy
• Not receiving Cosentyx in combination with another targeted immunomodulator [Enbrel, Cimzia, Simponi, Orencia, adalimumab, Xeljanz, Olumiant, Rinvoq]

Approval duration

12 months